Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$88.72
At close: Mar 21, 4:00 PM EDT
$88.72
0.000.00%
After Hours: Mar 21, 4:00 PM EDT
Comments
Loading...
Blueprint Medicines Analyst Ratings and Price Targets | NASDAQ:BPMC | Benzinga
Blueprint Medicines Corp has a consensus price target of $118.12 based on the ratings of 26 analysts. The high is $168 issued by Goldman Sachs on May 6, 2024. The low is $43 issued by SVB Leerink on June 5, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, Jefferies, and Scotiabank on March 20, 2025, March 17, 2025, and March 7, 2025, respectively. With an average price target of $128.33 between Morgan Stanley, Jefferies, and Scotiabank, there's an implied 44.65% upside for Blueprint Medicines Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Jefferies
Scotiabank
Citizens Capital Markets
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Blueprint Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 12.71% | Morgan Stanley | Judah Frommer65% | $120 → $100 | Assumes | → Equal-Weight | Get Alert |
| 03/17/2025 | Buy Now | 52.16% | Jefferies | Michael Yee58% | → $135 | Initiates | → Buy | Get Alert |
| 03/07/2025 | Buy Now | 69.07% | Scotiabank | Louise Chen59% | → $150 | Initiates | → Sector Outperform | Get Alert |
| 03/03/2025 | Buy Now | 40.89% | Citizens Capital Markets | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/14/2025 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/14/2025 | Buy Now | 49.91% | Needham | Ami Fadia62% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2025 | Buy Now | 52.16% | HC Wainwright & Co. | Andrew Fein57% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 49.91% | Needham | Ami Fadia62% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 45.4% | JP Morgan | Brian Cheng37% | $126 → $129 | Maintains | Overweight | Get Alert |
| 01/27/2025 | Buy Now | 34.13% | Piper Sandler | Christopher Raymond57% | $109 → $119 | Maintains | Neutral | Get Alert |
| 01/15/2025 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/13/2025 | Buy Now | 39.77% | Wedbush | David Nierengarten62% | $135 → $124 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 52.16% | Needham | Ami Fadia62% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2025 | Buy Now | 57.8% | Stephens & Co. | Sudan Loganathan31% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 12/17/2024 | Buy Now | 52.16% | Needham | Ami Fadia62% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | — | Guggenheim | Michael Schmidt55% | — | Reiterates | Buy → Buy | Get Alert |
| 12/09/2024 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/15/2024 | Buy Now | 52.16% | HC Wainwright & Co. | Andrew Fein57% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 52.16% | Needham | Ami Fadia62% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 42.02% | JP Morgan | Brian Cheng37% | → $126 | Initiates | → Overweight | Get Alert |
| 10/31/2024 | Buy Now | 70.2% | Wells Fargo | Derek Archila59% | $153 → $151 | Maintains | Overweight | Get Alert |
| 10/31/2024 | Buy Now | 52.16% | HC Wainwright & Co. | Andrew Fein57% | $135 → $135 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 52.16% | Needham | Ami Fadia62% | $133 → $135 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 49.91% | Needham | Ami Fadia62% | $133 → $133 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | -0.81% | UBS | David Dai26% | → $88 | Initiates | → Neutral | Get Alert |
| 08/05/2024 | Buy Now | 49.91% | Needham | Ami Fadia62% | $130 → $133 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 55.55% | Guggenheim | Michael Schmitz42% | $130 → $138 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 43.15% | Baird | Joel Beatty68% | $112 → $127 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | 46.53% | Needham | Ami Fadia62% | $130 → $130 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 18.35% | Barclays | Peter Lawson42% | $75 → $105 | Maintains | Equal-Weight | Get Alert |
| 07/12/2024 | Buy Now | 29.62% | Morgan Stanley | Michael Ulz58% | $110 → $115 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 40.89% | Oppenheimer | Matthew Biegler37% | $114 → $125 | Maintains | Outperform | Get Alert |
| 06/28/2024 | Buy Now | 46.53% | Needham | Ami Fadia62% | $130 → $130 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/14/2024 | Buy Now | 57.8% | Stephens & Co. | Sudan Loganathan31% | → $140 | Initiates | → Overweight | Get Alert |
| 05/06/2024 | Buy Now | 9.33% | Leerink Partners | Andrew Berens48% | $50 → $97 | Upgrade | Underperform → Market Perform | Get Alert |
| 05/06/2024 | Buy Now | 89.36% | Goldman Sachs | Terence Flynn66% | $121 → $168 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -14.34% | Citigroup | David Lebowitz51% | $65 → $76 | Maintains | Sell | Get Alert |
| 05/03/2024 | Buy Now | 52.16% | HC Wainwright & Co. | Andrew Fein57% | $125 → $135 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 40.89% | JMP Securities | Reni Benjamin46% | $114 → $125 | Maintains | Market Outperform | Get Alert |
| 05/03/2024 | Buy Now | -15.46% | Barclays | Peter Lawson42% | $70 → $75 | Maintains | Equal-Weight | Get Alert |
| 05/03/2024 | Buy Now | 17.22% | Piper Sandler | Christopher Raymond57% | $78 → $104 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | 46.53% | Needham | Ami Fadia62% | $97 → $130 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 9.33% | Needham | Ami Fadia62% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 40.89% | HC Wainwright & Co. | Andrew Fein57% | $125 → $125 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 23.99% | Wedbush | David Nierengarten62% | $110 → $110 | Reiterates | Outperform → Outperform | Get Alert |
| 04/26/2024 | Buy Now | 9.33% | Needham | Ami Fadia62% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 46.53% | Stifel | Bradley Canino41% | $120 → $130 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/26/2024 | Buy Now | 9.33% | Needham | Ami Fadia62% | $97 → $97 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | Buy Now | -26.74% | Citigroup | David Lebowitz51% | $54 → $65 | Maintains | Sell | Get Alert |
| 02/13/2024 | Buy Now | -21.1% | Barclays | Peter Lawson42% | $58 → $70 | Maintains | Equal-Weight | Get Alert |
| 01/16/2024 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | $114 → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/09/2024 | Buy Now | 9.33% | Stifel | Bradley Canino41% | $95 → $97 | Maintains | Buy | Get Alert |
| 12/22/2023 | Buy Now | 12.71% | Raymond James | Dane Leone45% | $85 → $100 | Maintains | Strong Buy | Get Alert |
| 12/19/2023 | Buy Now | 29.62% | Wells Fargo | Derek Archila59% | $86 → $115 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | -4.19% | HC Wainwright & Co. | Andrew Fein57% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 10/27/2023 | Buy Now | -4.19% | Oppenheimer | Matthew Biegler37% | → $85 | Upgrade | Perform → Outperform | Get Alert |
| 10/27/2023 | Buy Now | -28.99% | Morgan Stanley | Michael Ulz58% | $59 → $63 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -34.63% | Barclays | Peter Lawson42% | $46 → $58 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -16.59% | Needham | Ami Fadia62% | $66 → $74 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | -25.61% | Needham | Ami Fadia62% | $65 → $66 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/03/2023 | Buy Now | -33.5% | Morgan Stanley | Michael Ulz58% | $55 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | -6.45% | Goldman Sachs | Terence Flynn66% | $93 → $83 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -26.74% | Needham | Ami Fadia62% | → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | -4.19% | HC Wainwright & Co. | Andrew Fein57% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -26.74% | Needham | Ami Fadia62% | → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | — | Wells Fargo | Derek Archila59% | $55 → $83 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 07/14/2023 | Buy Now | -38.01% | Morgan Stanley | Michael Ulz58% | $55 → $55 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | -38.01% | Wells Fargo | Derek Archila59% | $48 → $55 | Maintains | Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | -51.53% | SVB Leerink | Andrew Berens48% | $48 → $43 | Downgrade | Market Perform → Underperform | Get Alert |
| 05/23/2023 | Buy Now | -7.57% | Guggenheim | Michael Schmidt55% | $78 → $82 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -15.46% | Wedbush | Liana Moussatos77% | → $75 | Reiterates | Outperform → Outperform | Get Alert |
| 05/23/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/23/2023 | Buy Now | -45.9% | Wells Fargo | Derek Archila59% | $47 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/23/2023 | Buy Now | -4.19% | HC Wainwright & Co. | Andrew Fein57% | $75 → $85 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -24.48% | Needham | Ami Fadia62% | $65 → $67 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -48.15% | Barclays | Peter Lawson42% | $44 → $46 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -38.01% | Morgan Stanley | Michael Ulz58% | $50 → $55 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | → Market Outperform | Get Alert |
| 05/05/2023 | Buy Now | -15.46% | HC Wainwright & Co. | Andrew Fein57% | $70 → $75 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | -26.74% | Needham | Ami Fadia62% | $56 → $65 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | -35.75% | Needham | Ami Fadia62% | → $57 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | → Market Outperform | Get Alert |
| 02/28/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | → Market Perform | Get Alert |
| 02/28/2023 | Buy Now | -35.75% | Needham | Ami Fadia62% | → $57 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -21.1% | HC Wainwright & Co. | Andrew Fein57% | → $70 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | -35.75% | Needham | Ami Fadia62% | → $57 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -57.17% | SVB Leerink | Andrew Berens48% | $45 → $38 | Maintains | Market Perform | Get Alert |
| 02/17/2023 | Buy Now | -4.19% | Raymond James | Dane Leone45% | $115 → $85 | Maintains | Strong Buy | Get Alert |
| 02/17/2023 | Buy Now | -21.1% | HC Wainwright & Co. | Andrew Fein57% | → $70 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | -35.75% | Needham | Ami Fadia62% | $60 → $57 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | -32.37% | Needham | Ami Fadia62% | → $60 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | -32.37% | Needham | Ami Fadia62% | → $60 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | -32.37% | Needham | Ami Fadia62% | → $60 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 28.49% | JMP Securities | Reni Benjamin46% | → $114 | Reiterates | → Market Outperform | Get Alert |
| 01/27/2023 | Buy Now | -43.64% | Morgan Stanley | Michael Ulz58% | $75 → $50 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Blueprint Medicines (BPMC) stock?
The latest price target for Blueprint Medicines (NASDAQ:BPMC) was reported by Morgan Stanley on March 20, 2025. The analyst firm set a price target for $100.00 expecting BPMC to rise to within 12 months (a possible 12.71% upside). 50 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Blueprint Medicines (BPMC)?
The latest analyst rating for Blueprint Medicines (NASDAQ:BPMC) was provided by Morgan Stanley, and Blueprint Medicines their equal-weight rating.
When was the last upgrade for Blueprint Medicines (BPMC)?
The last upgrade for Blueprint Medicines Corp happened on May 6, 2024 when Leerink Partners raised their price target to $97. Leerink Partners previously had an underperform for Blueprint Medicines Corp.
When was the last downgrade for Blueprint Medicines (BPMC)?
The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.
When is the next analyst rating going to be posted or updated for Blueprint Medicines (BPMC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Blueprint Medicines (BPMC) correct?
While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a with a price target of $120.00 to $100.00. The current price Blueprint Medicines (BPMC) is trading at is $88.72, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.